Tirzepatide Lyophilized Maʻemaʻe Kiʻekiʻe 99% Peptide Powder TR 10mg 15mg 20mg 30mg i kēlā me kēia hue no ke kō koko / maʻi diabetes

ʻO Tirzepatide kahi mea hou aku i ka glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist i ʻāpono ʻia ma ʻAmelika Hui Pū ʻIa ma ke ʻano he mea hoʻohui i ka meaʻai a me ka hoʻomaʻamaʻa e hoʻomaikaʻi ai i ka mana glycemic i nā pākeke me ka maʻi maʻi type 2 a ma lalo o ka hoʻokolokolo ʻana no ka hoʻohana ʻana i ka mālama ʻana i ke kaumaha mau, nā hanana ʻino koʻikoʻi o ka cardiovascular a me ka mālama ʻana i nā kūlana ʻē aʻe, e komo pū me ka puʻuwai puʻuwai me ka fraction a me ka meaʻai ʻole. steatohepatitis non-alcoholic. Ua hoʻolālā ʻia ka papahana hoʻokolohua lapaʻau ʻo Phase 3 SURPASS 1-5 e loiloi i ka pono a me ka palekana o ka tirzepatide subcutaneously i hoʻokahi pule i hoʻokahi pule (5, 10 a me 15 mg), ma ke ʻano he monotherapy a hui pū ʻana paha, ma kahi ākea ākea o ka poʻe me ka maʻi diabetes type 2. ʻO ka hoʻohana ʻana i ka tirzepatide i loko o nā haʻawina hauʻoli ua pili pū me ka hōʻemi nui ʻana o ka hemoglobin glycated (-1.87 a -2.59%, -20 a -28 mmol/mol) a me ke kaumaha o ke kino (-6.2 a i -12.9 kg), a me ka hoʻemi ʻana i nā ʻāpana e pili pinepine ana me ka piʻi ʻana o ka cardiometabolic risk e like me ke koko, visceral adiglycerides. Ua ʻae maikaʻi ʻia ʻo Tirzepatide, me ka haʻahaʻa haʻahaʻa o ka hypoglycaemia i ka wā i hoʻohana ʻia me ka ʻole o ka insulin a i ʻole ka insulin secretagogues a hōʻike i kahi ʻano palekana e like me ka GLP-1 receptor agonist class. No laila, hōʻike nā hōʻike mai kēia mau hoʻokolohua lapaʻau e hāʻawi ana ʻo tirzepatide i kahi manawa hou no ka hoʻohaʻahaʻa pono ʻana o ka hemoglobin glycated a me ke kaumaha o ke kino i nā pākeke me ka maʻi diabetes type 2.